Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pyrilamine maleate

Executive Summary

Nonprescription Drug Manufacturers Association submitted "industry protocol consensus" to FDA Oct. 13 for the study of pyrilamine maleate in premenstrual pain. Pyrilamine was listed as Category III in the Tentative Final Monograph on Orally Administered Menstrual Drugs after FDA concluded its efficacy for relief of premenstrual pain and mood changes was not proven. NDMA's new randomized, double-blind crossover study would test 30 mg pyrilamine maleate four times daily v. placebo in 72 women aged 18-45 for six months.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS016464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel